Replies to post #475786 on Anavex Life Sciences Corp (AVXL)

[Hosai]

Not sure how relevant but the notable finding COL24A1 was a variant not a gene. The PDD analysis may have been focussed on gene expression levels rather than variants.

[12x]

The COL24A1 is also linked to PD per ChatGPT so the genetic clusters poster might have missed it. It would be nice to re-run the study with AD data.

What do you think of the "Significant Benefits" mean? It's interesting that typical wording like "significantly slowing" is not used. The "significantly" must be based on p-value but there is no placebo control group. Compared to ADNI? Even Leqembi did not calculate StatSig against ADNI.

PHASE IIB/III ATTENTION-AD STUDY: OVER THREE YEARS OF CONTINUOUS TREATMENT WITH ORAL BLARCAMESINE CONTINUES TO SIGNIFICANTLY BENEFITS EARLY ALZHEIMER'S DISEASE PATIENTS